Drug Trial Radar · NCT01623713
Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia
Last checked: Nov 20, 2026Latest source record: Nov 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Jun 2012
Primary completion
Oct 2013
Study completion Nov 2013
Sponsor
- Lead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.
Conditions
- Schizophrenia
- Iloperidone
- Efficacy
Interventions
iloperidoneDrug
Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
RisperidoneDrug
Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Positive and Negative Symptom Scale(PANSS)-Total ScoreTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sixth Hospital of Peking University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.